HRTX
Heron Therapeutics Inc
Price:  
2.87 
USD
Volume:  
1,958,509.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

HRTX EV/EBITDA

-529.1%
Upside

As of 2024-02-21, the EV/EBITDA ratio of Heron Therapeutics Inc (HRTX) is -4.67. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. HRTX's latest enterprise value is 545.20 mil USD. HRTX's TTM EBITDA according to its financial statements is -116.75 mil USD. Dividing these 2 quantities gives us the above HRTX EV/EBITDA ratio.

Note: valuation result may not be accurate due to the company's negative EBITDA.

Range Selected
Trailing P/E multiples 11.8x - 19.6x 12.1x
Forward P/E multiples 16.6x - 19.0x 17.6x
Fair Price (13.71) - (15.51) (12.32)
Upside -577.6% - -640.5% -529.1%
2.87 USD
Stock Price
(12.32) USD
Fair Price

HRTX EV/EBITDA - Historical EV/EBITDA Data

Date EV/EBITDA
2024-02-21 -3.48
2024-02-20 -3.60
2024-02-16 -3.60
2024-02-15 -3.61
2024-02-14 -3.41
2024-02-13 -3.15
2024-02-12 -3.30
2024-02-09 -3.05
2024-02-08 -2.95
2024-02-07 -2.83
2024-02-06 -2.91
2024-02-05 -2.80
2024-02-02 -3.00
2024-02-01 -3.01
2024-01-31 -3.02
2024-01-30 -3.12
2024-01-29 -3.17
2024-01-26 -3.12
2024-01-25 -3.36
2024-01-24 -3.28
2024-01-23 -2.76
2024-01-22 -2.93
2024-01-19 -2.62
2024-01-18 -2.62
2024-01-17 -2.76
2024-01-16 -2.76
2024-01-12 -2.70
2024-01-11 -2.70
2024-01-10 -2.79
2024-01-09 -2.83
2024-01-08 -2.62
2024-01-05 -2.22
2024-01-04 -2.17
2024-01-03 -2.14
2024-01-02 -2.37
2023-12-29 -2.13
2023-12-28 -2.18
2023-12-27 -2.09
2023-12-26 -2.22
2023-12-22 -2.24
2023-12-21 -2.18
2023-12-20 -2.03
2023-12-19 -2.18
2023-12-18 -2.18
2023-12-15 -2.27
2023-12-14 -2.28
2023-12-13 -2.11
2023-12-12 -2.11
2023-12-11 -1.91
2023-12-08 -1.87